gamma-aminobutyric acid has been researched along with Opioid-Related Disorders in 41 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Opioid-Related Disorders: Disorders related to or resulting from abuse or misuse of OPIOIDS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Participants were randomly assigned (2:1) to daily dosing with ASP8062 25 mg or placebo on days 1-10." | 3.30 | A phase 1 randomized, placebo-controlled study to investigate potential interactions between ASP8062, a positive allosteric modulator of the GABA ( Alsharif, MN; Blahunka, P; Blauwet, MB; Erdman, J; Heo, N; Ito, M; Kelsh, D; Marek, GJ; Spence, A; Walzer, M, 2023) |
| "Gabapentin is a potentially useful drug in alleviating the hyperexcitatory painful states in the control of opiate dependence in acute detoxification and the stabilization phase." | 2.78 | The effects of gabapentin on methadone based addiction treatment: a randomized controlled trial. ( Alavinia, M; Moghadam, MS, 2013) |
| "Group A showed more withdrawal symptoms whereas the most common complain of group B was sedation particularly during the first three days." | 2.78 | The effects of gabapentin on methadone based addiction treatment: a randomized controlled trial. ( Alavinia, M; Moghadam, MS, 2013) |
| " Using a double-blind, randomized, crossover design, 16 healthy volunteers were administered (in separate sessions) capsules containing placebo, 75 mg pregabalin, 150 mg pregabalin, 10 mg oxycodone, and 75 mg pregabalin combined with 10 mg oxycodone." | 2.77 | Subjective, psychomotor, and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteers. ( Coalson, DW; Paice, JA; Zacny, JP, 2012) |
| "Interestingly, opioids induce hyperalgesia via many of the same neuro-inflammatory and central sensitization processes that occur with the development of neuropathic pain." | 2.75 | Gabapentin improves cold-pressor pain responses in methadone-maintained patients. ( Compton, P; Kehoe, P; Ling, W; Sinha, K; Torrington, MA, 2010) |
| "Severity of subjective withdrawal symptoms using the Subjective Opiate Withdrawal Scale at six stages." | 2.73 | Effect of add-on gabapentin on opioid withdrawal symptoms in opium-dependent patients. ( Kheirabadi, GR; Maracy, MR; Ranjkesh, M; Salehi, M, 2008) |
| "The neural mechanisms underlying opioid abuse and addiction are still not fully understood." | 2.72 | Progress in opioid reward research: From a canonical two-neuron hypothesis to two neural circuits. ( Galaj, E; Xi, ZX, 2021) |
| "Buprenorphine was superior to clonidine in controlling severe withdrawal symptoms in an outpatient setting (RR 0." | 2.58 | Pharmacological therapies for management of opium withdrawal. ( Amato, L; Amin-Esmaeili, M; Gholami, J; Hoseinie, L; Rahimi-Movaghar, A; Yousefi-Nooraie, R, 2018) |
| "However, it seems that opium withdrawal symptoms are significant, especially at days 2 to 4 after discontinuation of opium." | 2.58 | Pharmacological therapies for management of opium withdrawal. ( Amato, L; Amin-Esmaeili, M; Gholami, J; Hoseinie, L; Rahimi-Movaghar, A; Yousefi-Nooraie, R, 2018) |
| "All patients had substance use disorders, the large majority (72 %) to more than one substance." | 1.43 | Abuse of Gabapentin is Associated with Opioid Addiction. ( Bastiaens, L; Galus, J; Mazur, C, 2016) |
| "Fifty-eight percent had an opioid use disorder, again mostly in combination with other drugs and/or alcohol." | 1.43 | Abuse of Gabapentin is Associated with Opioid Addiction. ( Bastiaens, L; Galus, J; Mazur, C, 2016) |
| "These findings indicate that opioid dependence induces efficacious coupling of mu-receptors to presynaptic inhibition in GABAergic nerve terminals via adenylyl cyclase- and protein kinase A-dependent processes in PAG." | 1.30 | Enhanced opioid efficacy in opioid dependence is caused by an altered signal transduction pathway. ( Bagley, EE; Christie, MJ; Connor, M; Ingram, SL; Vaughan, CW, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.88) | 18.7374 |
| 1990's | 2 (4.88) | 18.2507 |
| 2000's | 8 (19.51) | 29.6817 |
| 2010's | 23 (56.10) | 24.3611 |
| 2020's | 6 (14.63) | 2.80 |
| Authors | Studies |
|---|---|
| Kumar, AS | 1 |
| Khanra, S | 1 |
| Goyal, N | 1 |
| Dharani, R | 1 |
| Roy, C | 1 |
| Ito, M | 1 |
| Walzer, M | 1 |
| Blauwet, MB | 1 |
| Spence, A | 1 |
| Heo, N | 1 |
| Kelsh, D | 1 |
| Blahunka, P | 1 |
| Erdman, J | 1 |
| Alsharif, MN | 1 |
| Marek, GJ | 1 |
| Li, JN | 1 |
| Liu, XL | 1 |
| Li, L | 1 |
| Kallupi, M | 1 |
| Carrette, LLG | 1 |
| Kononoff, J | 1 |
| Solberg Woods, LC | 1 |
| Palmer, AA | 1 |
| Schweitzer, P | 1 |
| George, O | 1 |
| de Guglielmo, G | 1 |
| Galaj, E | 1 |
| Xi, ZX | 2 |
| Chan, JCY | 1 |
| Waddell, TK | 1 |
| Yasufuku, K | 1 |
| Keshavjee, S | 1 |
| Donahoe, LL | 1 |
| Levenbrown, Y | 1 |
| Hossain, MJ | 1 |
| Keith, JP | 1 |
| Burr, K | 1 |
| Hesek, A | 1 |
| Shaffer, TH | 1 |
| Yao, LL | 1 |
| Cao, JR | 1 |
| Lyu, CJ | 1 |
| Fan, FF | 1 |
| Wang, HP | 1 |
| Cao, HW | 1 |
| Huang, J | 1 |
| Mei, LH | 1 |
| He, P | 1 |
| Li, Y | 1 |
| Zhang, R | 1 |
| Ren, M | 1 |
| Liu, H | 1 |
| Yang, M | 1 |
| Liu, X | 1 |
| Wang, Z | 1 |
| Xu, C | 1 |
| Guan, J | 1 |
| Wei, B | 1 |
| Liu, Y | 1 |
| Swinkels, BM | 1 |
| Ten Berg, JM | 1 |
| Kelder, JC | 1 |
| Vermeulen, FE | 1 |
| van Boven, WJ | 1 |
| de Mol, BA | 1 |
| Huang, K | 1 |
| Yang, X | 1 |
| Ma, Y | 1 |
| Sun, G | 1 |
| Nitin, N | 1 |
| Wickramasinghe, A | 1 |
| Xiao, Y | 1 |
| Kobayashi, N | 1 |
| Wang, S | 1 |
| Scherpelz, KP | 1 |
| Yamazaki, T | 1 |
| Meredith, SC | 1 |
| Ishii, Y | 1 |
| Phoonsawat, K | 1 |
| Khachornsakkul, K | 1 |
| Ratnarathorn, N | 1 |
| Henry, CS | 1 |
| Dungchai, W | 1 |
| Zareena, B | 1 |
| Khadim, A | 1 |
| Jeelani, SUY | 1 |
| Hussain, S | 1 |
| Ali, A | 1 |
| Musharraf, SG | 1 |
| Zhuo, X | 1 |
| Jiang, W | 1 |
| Qian, G | 1 |
| Chen, J | 1 |
| Yu, T | 1 |
| Luo, L | 1 |
| Lu, L | 1 |
| Chen, Y | 1 |
| Yin, S | 1 |
| Hong, NJ | 1 |
| Gonzalez-Vicente, A | 1 |
| Saez, F | 1 |
| Garvin, JL | 1 |
| Hede, KTC | 1 |
| Christensen, BB | 1 |
| Olesen, ML | 1 |
| Thomsen, JS | 1 |
| Foldager, CB | 1 |
| Toh, WS | 1 |
| Lim, SK | 1 |
| Lind, MC | 1 |
| Woods, LM | 1 |
| Connelly, CD | 1 |
| Doğan, MF | 1 |
| Başak Türkmen, N | 1 |
| Taşlıdere, A | 1 |
| Şahin, Y | 1 |
| Çiftçi, O | 1 |
| Rudolf, G | 1 |
| Walsh, J | 1 |
| Plawman, A | 1 |
| Gianutsos, P | 1 |
| Alto, W | 1 |
| Mancl, L | 1 |
| Rudolf, V | 1 |
| Service, RF | 1 |
| Hamed, A | 1 |
| Kursa, MB | 1 |
| Throckmorton, DC | 1 |
| Gottlieb, S | 1 |
| Woodcock, J | 1 |
| Rahimi-Movaghar, A | 1 |
| Gholami, J | 1 |
| Amato, L | 1 |
| Hoseinie, L | 1 |
| Yousefi-Nooraie, R | 1 |
| Amin-Esmaeili, M | 1 |
| Sanders, NC | 1 |
| Mancino, MJ | 1 |
| Gentry, WB | 1 |
| Guise, JB | 1 |
| Bickel, WK | 1 |
| Thostenson, J | 1 |
| Oliveto, AH | 1 |
| Bicknell, M | 1 |
| Moghadam, MS | 1 |
| Alavinia, M | 1 |
| Baird, CR | 1 |
| Fox, P | 1 |
| Colvin, LA | 1 |
| Torrens, M | 1 |
| Fonseca, F | 1 |
| Morisot, N | 1 |
| Rouibi, K | 1 |
| Contarino, A | 1 |
| Satish, R | 1 |
| Kandasamy, A | 1 |
| Jayarajan, D | 1 |
| Benegal, V | 1 |
| Smith, RV | 1 |
| Lofwall, MR | 1 |
| Havens, JR | 1 |
| Bastiaens, L | 1 |
| Galus, J | 1 |
| Mazur, C | 1 |
| Horsfall, JT | 1 |
| Sprague, JE | 1 |
| Weinstein, ZM | 1 |
| Cheng, DM | 1 |
| Quinn, E | 1 |
| Hui, D | 1 |
| Kim, H | 1 |
| Gryczynski, G | 1 |
| Samet, JH | 1 |
| Blum, K | 1 |
| Gold, MS | 1 |
| Jacobs, W | 1 |
| McCall, WV | 1 |
| Febo, M | 1 |
| Baron, D | 1 |
| Dushaj, K | 1 |
| Demetrovics, Z | 1 |
| Badgaiyan, RD | 1 |
| Kheirabadi, GR | 2 |
| Ranjkesh, M | 2 |
| Maracy, MR | 2 |
| Salehi, M | 2 |
| Guo, Y | 1 |
| Wang, HL | 1 |
| Xiang, XH | 1 |
| Zhao, Y | 1 |
| Omelchenko, N | 1 |
| Sesack, SR | 1 |
| Compton, P | 1 |
| Kehoe, P | 1 |
| Sinha, K | 1 |
| Torrington, MA | 1 |
| Ling, W | 1 |
| Zacny, JP | 1 |
| Paice, JA | 1 |
| Coalson, DW | 1 |
| Kämmerer, N | 1 |
| Lemenager, T | 1 |
| Grosshans, M | 1 |
| Kiefer, F | 1 |
| Hermann, D | 1 |
| Imhof, K | 1 |
| Krall, K | 1 |
| Gombotz, H | 1 |
| Bagley, EE | 2 |
| Gerke, MB | 1 |
| Vaughan, CW | 2 |
| Hack, SP | 1 |
| Christie, MJ | 2 |
| Frenois, F | 1 |
| Stinus, L | 1 |
| Di Blasi, F | 1 |
| Cador, M | 1 |
| Le Moine, C | 1 |
| Schmidt, LG | 1 |
| Bleich, S | 1 |
| Boening, J | 1 |
| Buehringer, G | 1 |
| Kornhuber, J | 1 |
| Weijers, HG | 1 |
| Wiesbeck, GA | 1 |
| Wolfgramm, J | 1 |
| Havemann-Reinecke, U | 1 |
| McDaid, J | 1 |
| Dallimore, JE | 1 |
| Mackie, AR | 1 |
| Napier, TC | 1 |
| Nutt, D | 1 |
| Lingford-Hughes, A | 1 |
| Bracha, HS | 1 |
| Kleinman, JE | 1 |
| Nicolodi, M | 1 |
| Del Bianco, PL | 1 |
| Sicuteri, F | 1 |
| Ingram, SL | 1 |
| Connor, M | 1 |
| Stein, EA | 1 |
| Costentin, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Opioid-Induced Hyperalgesia in Prescription Opioid Abusers: Effects of Pregabalin[NCT01821430] | Phase 2 | 4 participants (Actual) | Interventional | 2013-03-31 | Terminated (stopped due to poor recruitment) | ||
| Examination of Palonosetron and Hydroxyzine Pre-treatment as a Possible Method to Reduce the Objective Signs of Experimentally-induced Acute Opioid Withdrawal in Humans: a Double-blind, Randomized, Placebo-controlled Crossover Study[NCT00661674] | 10 participants (Actual) | Interventional | 2008-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The OOWS is a 13-item instrument documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. Maximum score possible = 13, minimum score possible = 0. T=15 minutes post naloxone administration coordinates with T = 180 (min) for the entire study session.~OOWS scores at T=180 is the primary outcome measure of the study compared with baseline OOWS scores at T=-30 (30 minutes prior to study medication administration). Reported time frames are in relation to time past since administration of study medications.~Mean post-Naloxone OOWS scores (+/- SEM) were determined for pretreatment groups" (NCT00661674)
Timeframe: Change from baseline in OOWS score at 180 minutes (15 minutes post naloxone administration)
| Intervention | units on a scale (OOWS Scale) (Mean) |
|---|---|
| Placebo | 3.5 |
| Palonosetron | 1.0 |
| Palonosetron + Hydroxyzine | 0 |
"The SOWS score is composed of 16 subjective symptoms rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. 15 minutes post naloxone administration coordinates with T = 180 (min) for the entire study session.~The highest score possible (64) would indicate that the individual was experiencing every symptom of opioid withdrawal to the fullest extent possible while the lowest score (0) would indicate that the individual was not experiencing any symptoms of opioid withdrawal.~Mean post-naloxone SOWS scores (+/- SEM) were computed for pretreatment groups: Placebo, palonosetron, and palonosetron with hydroxyzine" (NCT00661674)
Timeframe: Change from baseline in SOWS score at 180 minutes (15 minutes post naloxone administration)
| Intervention | units on a scale (SOWS Scale) (Mean) |
|---|---|
| Placebo | 6.0 |
| Palonosetron | 4.0 |
| Palonosetron + Hydroxyzine | 3.5 |
8 reviews available for gamma-aminobutyric acid and Opioid-Related Disorders
| Article | Year |
|---|---|
Progress in opioid reward research: From a canonical two-neuron hypothesis to two neural circuits.
Topics: Analgesics, Opioid; Animals; Behavior, Addictive; Dopamine; Dopaminergic Neurons; gamma-Aminobutyric | 2021 |
Pharmacological therapies for management of opium withdrawal.
Topics: Amantadine; Amines; Baclofen; Buprenorphine; Clonidine; Cyclohexanecarboxylic Acids; Gabapentin; gam | 2018 |
The Pharmacology and Toxicology of the 'Holy Trinity'.
Topics: Analgesics, Opioid; Animals; Benzodiazepines; Carisoprodol; Contraindications; Dopamine; Drug Dosage | 2017 |
Neurogenetics of acute and chronic opiate/opioid abstinence: treating symptoms and the cause.
Topics: Animals; Cannabinoids; Dopamine; Drug-Seeking Behavior; Evidence-Based Medicine; gamma-Aminobutyric | 2017 |
The role of glutamate and its receptors in mesocorticolimbic dopaminergic regions in opioid addiction.
Topics: Animals; Brain; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Neurons; Opioid Peptides; | 2009 |
Addiction: the clinical interface.
Topics: Animals; Behavior, Addictive; Brain; Dopamine; Drug Design; Drug Partial Agonism; gamma-Aminobutyric | 2008 |
Postmortem studies in psychiatry.
Topics: Alcoholism; Alzheimer Disease; Brain Chemistry; Cholecystokinin; Depressive Disorder; Dopamine; Endo | 1984 |
[Modulation of dopaminergic receptor sensitivity in the central nervous system: important parameters in synaptic function regulation].
Topics: Acetylcholine; Adenylyl Cyclases; Animals; Antipsychotic Agents; Apomorphine; Behavior; Corpus Stria | 1979 |
8 trials available for gamma-aminobutyric acid and Opioid-Related Disorders
| Article | Year |
|---|---|
Adjunctive High-Definition Transcranial Direct Current Stimulation in Brain Glutamate-Glutamine and γ-Aminobutyric Acid, Withdrawal and Craving During Early Abstinence Among Patients With Opioid Use Disorder on Buprenorphine-Naloxone: A Proton Magnetic Re
Topics: Brain; Buprenorphine, Naloxone Drug Combination; Craving; Double-Blind Method; Electroconvulsive The | 2022 |
A phase 1 randomized, placebo-controlled study to investigate potential interactions between ASP8062, a positive allosteric modulator of the GABA
Topics: Analgesics, Opioid; Double-Blind Method; gamma-Aminobutyric Acid; Humans; Morphine; Opioid-Related D | 2023 |
Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure.
Topics: Adult; Amines; Buprenorphine; Cyclohexanecarboxylic Acids; Diagnostic and Statistical Manual of Ment | 2013 |
The effects of gabapentin on methadone based addiction treatment: a randomized controlled trial.
Topics: Adult; Amines; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Double-Blind Method; Drug Therapy, C | 2013 |
Effect of add-on gabapentin on opioid withdrawal symptoms in opium-dependent patients.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2008 |
Gabapentin improves cold-pressor pain responses in methadone-maintained patients.
Topics: Adult; Amines; Analgesics, Non-Narcotic; Cold Temperature; Cyclohexanecarboxylic Acids; Double-Blind | 2010 |
Importance of gabapentin dose in treatment of opioid withdrawal.
Topics: Adult; Amines; Analgesics, Opioid; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Response Relat | 2011 |
Subjective, psychomotor, and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteers.
Topics: Adult; Analgesics; Analgesics, Opioid; Anticonvulsants; Cross-Over Studies; Dose-Response Relationsh | 2012 |
25 other studies available for gamma-aminobutyric acid and Opioid-Related Disorders
| Article | Year |
|---|---|
Prefrontal GABA and glutamate levels correlate with impulsivity and cognitive function of prescription opioid addicts: A
Topics: Adult; Antitussive Agents; Codeine; Cognitive Dysfunction; Female; gamma-Aminobutyric Acid; Glutamic | 2020 |
Nociceptin attenuates the escalation of oxycodone self-administration by normalizing CeA-GABA transmission in highly addicted rats.
Topics: Amygdala; Animals; gamma-Aminobutyric Acid; Humans; Male; Nociceptin; Opioid Peptides; Opioid-Relate | 2020 |
Topics: Acetic Acid; Albumins; Alkaline Phosphatase; Alkaloids; Amyloid beta-Peptides; Analgesics, Opioid; A | 2021 |
A novel non-opioid protocol for medically supervised opioid withdrawal and transition to antagonist treatment.
Topics: Adult; Amines; Analgesics, Opioid; Buprenorphine; Clonidine; Counseling; Cyclohexanecarboxylic Acids | 2018 |
Chemists seek antiaddiction drugs to battle hijacked brain.
Topics: 4-Aminobutyrate Transaminase; Animals; Behavior, Addictive; Brain; Craving; Drug Design; Enzyme Inhi | 2018 |
Inter-individual differences in serotonin and glutamate co-transmission reflect differentiation in context-induced conditioned 50-kHz USVs response after morphine withdrawal.
Topics: Animals; Behavior, Animal; Brain; Conditioning, Psychological; Disease Models, Animal; gamma-Aminobu | 2018 |
The FDA and the Next Wave of Drug Abuse - Proactive Pharmacovigilance.
Topics: Amines; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Drug Utilization | 2018 |
The pain of pregabalin prescribing in prisons.
Topics: Analgesics; gamma-Aminobutyric Acid; General Practice; Guideline Adherence; Humans; Inappropriate Pr | 2013 |
Gabapentinoid abuse in order to potentiate the effect of methadone: a survey among substance misusers.
Topics: Amines; Behavior, Addictive; Cyclohexanecarboxylic Acids; Data Collection; Drug Synergism; Gabapenti | 2014 |
Role of ALDH5A1 in methadone treatment.
Topics: gamma-Aminobutyric Acid; Humans; Methadone; Narcotics; Opiate Substitution Treatment; Opioid-Related | 2014 |
CRF2 Receptor Deficiency Eliminates the Long-Lasting Vulnerability of Motivational States Induced by Opiate Withdrawal.
Topics: Animals; Anxiety; Brain; Conditioning, Operant; Disease Models, Animal; Dopamine; Female; gamma-Amin | 2015 |
Gabapentin dependence in a patient with opioid dependence syndrome.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; | 2015 |
Abuse and diversion of gabapentin among nonmedical prescription opioid users in Appalachian Kentucky.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; | 2015 |
Abuse of Gabapentin is Associated with Opioid Addiction.
Topics: Adult; Amines; Attention Deficit Disorder with Hyperactivity; Comorbidity; Criminals; Cyclohexanecar | 2016 |
Psychoactive medications and disengagement from office based opioid treatment (obot) with buprenorphine.
Topics: Adult; Amines; Analgesics, Opioid; Buprenorphine; Clonidine; Cyclohexanecarboxylic Acids; Female; Ga | 2017 |
Periaqueductal gray afferents synapse onto dopamine and GABA neurons in the rat ventral tegmental area.
Topics: Animals; Brain Mapping; Dopamine; Excitatory Postsynaptic Potentials; gamma-Aminobutyric Acid; Gluta | 2010 |
[Pregabalin for the reduction of opiate withdrawal symptoms].
Topics: Adult; Anticonvulsants; Drug Administration Schedule; gamma-Aminobutyric Acid; Heroin Dependence; Hu | 2012 |
[Life-threatening opioid overdose. Decoding the physician pin code of a patient-controlled anesthesia pump by patients].
Topics: Adolescent; Adult; Analgesia, Patient-Controlled; Analgesics, Opioid; Codeine; Critical Care; Drug O | 2012 |
GABA transporter currents activated by protein kinase A excite midbrain neurons during opioid withdrawal.
Topics: Action Potentials; Adaptation, Physiological; Animals; Chloride Channels; Cyclic AMP-Dependent Prote | 2005 |
A specific limbic circuit underlies opiate withdrawal memories.
Topics: Amygdala; Animals; Appetitive Behavior; Avoidance Learning; Conditioning, Classical; Delayed-Action | 2005 |
Advances in alcoholism research in Germany.
Topics: Alcohol Withdrawal Delirium; Alcoholism; Animals; Brain; Comorbidity; Dopamine; Early Diagnosis; gam | 2005 |
Changes in accumbal and pallidal pCREB and deltaFosB in morphine-sensitized rats: correlations with receptor-evoked electrophysiological measures in the ventral pallidum.
Topics: Action Potentials; Analysis of Variance; Animals; Behavior, Animal; Benzazepines; Blotting, Western; | 2006 |
Modulation of excitatory amino acids pathway: a possible therapeutic approach to chronic daily headache associated with analgesic drugs abuse.
Topics: Acetates; Adult; Amines; Chronic Disease; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagon | 1997 |
Enhanced opioid efficacy in opioid dependence is caused by an altered signal transduction pathway.
Topics: 4-Aminopyridine; Adenylyl Cyclases; Adrenergic alpha-Agonists; Animals; Clonidine; Cyclic AMP-Depend | 1998 |
Increased mesolimbic GABA concentration blocks heroin self-administration in the rat.
Topics: 4-Aminobutyrate Transaminase; Animals; Baclofen; Behavior, Animal; Bicuculline; Enzyme Inhibitors; G | 2000 |